Innate Immunotherapeutics Ltd (IIL)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Innate Immunotherapeutics Ltd (IIL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013225
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Innate Immunotherapeutics Ltd (Innate Immunotherapeutics), formerly Innate Therapeutics Ltd is a medical biotechnology company that develops therapeutic drugs for the treatment of cancer and infectious diseases. The company designs and develops immunomodulator microparticle technology. Innate Immunotherapeutics’ lead drug candidate MIS416 is a microparticle and non-immunogenic, cytosolically-active TLR-9 and NOD-2 ligands, which is used for cancer therapy and acts as an anti-metastatic agent. The company uses microparticle platform technology that induces the human immune system to fight against various cancers and infections; and to design preventive vaccines for influenza, cancer, malaria, or tuberculosis. The company offers products and services to treat auto-immune diseases and infectious diseases. It has operations in Australia and New Zealand. Innate Immunotherapeutics is headquartered in Sydney, New South Wales, Australia.

Innate Immunotherapeutics Ltd (IIL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Innate Immunotherapeutics Raises USD1.5 Million in Private Placement of Shares 10
Innate Immunotherapeutics Raises USD1.9 Million in Private Placement of Shares 11
Innate Immunotherapeutics Raises USD2.3 Million in Rights Offering of Shares 13
Innate Immunotherapeutics Raises USD3 Million in Private Placement of Shares 15
Innate Immunotherapeutics Completes IPO For US$9 Million 16
Innate Immunotherapeutics Announces Public Offering Of Shares For US$10 Million 18
Innate Immunotherapeutics Ltd – Key Competitors 19
Innate Immunotherapeutics Ltd – Key Employees 20
Innate Immunotherapeutics Ltd – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Other Significant Developments 22
Oct 30, 2017: Innate Immunotherapeutics: 4C Quarterly Cash Flow Report 22
Jul 28, 2017: Innate Immunotherapeutics: 4C Quarterly Cash Flow Report 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Innate Immunotherapeutics Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Innate Immunotherapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Innate Immunotherapeutics Raises USD1.5 Million in Private Placement of Shares 10
Innate Immunotherapeutics Raises USD1.9 Million in Private Placement of Shares 11
Innate Immunotherapeutics Raises USD2.3 Million in Rights Offering of Shares 13
Innate Immunotherapeutics Raises USD3 Million in Private Placement of Shares 15
Innate Immunotherapeutics Completes IPO For US$9 Million 16
Innate Immunotherapeutics Announces Public Offering Of Shares For US$10 Million 18
Innate Immunotherapeutics Ltd, Key Competitors 19
Innate Immunotherapeutics Ltd, Key Employees 20
Innate Immunotherapeutics Ltd, Other Locations 21

★海外企業調査レポート[Innate Immunotherapeutics Ltd (IIL)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Acxiom Corporation:企業の戦略・SWOT・財務分析
    Acxiom Corporation - Strategy, SWOT and Corporate Finance Report Summary Acxiom Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Hoya Corporation:企業の戦略・SWOT・財務情報
    Hoya Corporation - Strategy, SWOT and Corporate Finance Report Summary Hoya Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Sasol Ltd (SOL):企業の財務・戦略的SWOT分析
    Sasol Ltd (SOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • BaroFold Inc-製薬・医療分野:企業M&A・提携分析
    Summary BaroFold Inc (BaroFold) is a biotechnology company that provides protein refolding services. The company offers services such as research study services, optimization study services, and process implementation services. Its optimization study services include confirm analytical services, res …
  • Alinma Bank:企業の戦略・SWOT・財務分析
    Alinma Bank - Strategy, SWOT and Corporate Finance Report Summary Alinma Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Covanta Holding Corporation
    Covanta Holding Corporation - Strategy, SWOT and Corporate Finance Report Summary Covanta Holding Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Steel Excel Inc (SXCL):企業の財務・戦略的SWOT分析
    Summary Steel Excel Inc (Steel Excel) is a provider of technology consulting and business development solutions. The company’s services comprise rogue pressure services, sun well services, black hawk energy services, functional fitness facilities, sports training, strength and conditioning gym facil …
  • Kane Biotech Inc (KNE)-医療機器分野:企業M&A・提携分析
    Summary Kane Biotech Inc (Kane Biotech) is a developer of pharmaceutical products that prevent and remove microbial biofilms. The company uses patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. It develop …
  • Rev1 Ventures Inc.:企業のM&A・事業提携・投資動向
    Rev1 Ventures Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Rev1 Ventures Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Spherix Inc (SPEX):企業の財務・戦略的SWOT分析
    Spherix Inc (SPEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • First Abu Dhabi Bank (FAB):企業の財務・戦略的SWOT分析
    First Abu Dhabi Bank (FAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Guided Therapeutics Inc (GTHP):企業の財務・戦略的SWOT分析
    Summary Guided Therapeutics Inc (GTI), formerly SpectRx Inc is a biotechnology company that offers platform technology for the early detection of disease that leads to cancer. The company provides products for the non-invasive cervical cancer detection markets. Its products include luviva, a non-inv …
  • KapStone Paper and Packaging Corporation:企業の戦略・SWOT・財務情報
    KapStone Paper and Packaging Corporation - Strategy, SWOT and Corporate Finance Report Summary KapStone Paper and Packaging Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Isrotel Hotels Management Inc.:企業の戦略・SWOT・財務分析
    Isrotel Hotels Management Inc. - Strategy, SWOT and Corporate Finance Report Summary Isrotel Hotels Management Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Camlin Fine Sciences Limited:戦略・SWOT・企業財務分析
    Camlin Fine Sciences Limited - Strategy, SWOT and Corporate Finance Report Summary Camlin Fine Sciences Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Industrial Alliance Insurance and Financial Services Inc.:企業のM&A・事業提携・投資動向
    Industrial Alliance Insurance and Financial Services Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Industrial Alliance Insurance and Financial Services Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includ …
  • Oncodesign SA (ALONC):企業の財務・戦略的SWOT分析
    Summary Oncodesign SA (Oncodesign) is a bio pharmaceutical company that discovers drugs to treat diseases with unmet medical needs. It is investigating LRRK2 inhibitor to treat Parkinson’s disease, RIPK2 inhibitor against autoimmune diseases, MNK1/2 inhibitor targeting cancer. The company offers dru …
  • CSE Global Limited (544):企業の財務・戦略的SWOT分析
    CSE Global Limited (544) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Deloitte Touche Tohmatsu Ltd:企業の戦略的SWOT分析
    Deloitte Touche Tohmatsu Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Acerus Pharmaceuticals Corp (ASP):製薬・医療:M&Aディール及び事業提携情報
    Summary Acerus Pharmaceuticals Corp (Acerus), formerly Trimel Pharmaceuticals Corporation develops, manufactures, markets and distributes novel innovative branded products. It focuses on providing men’s and women’s health. The company uses its proprietary drug delivery technology platforms, which in …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆